NCT06038838 is a NA clinical trial of Tioga TMVR System in Mitral Regurgitation, sponsored by Tioga Cardiovascular, Inc..

Who is sponsoring NCT06038838?

NCT06038838 is sponsored by Tioga Cardiovascular, Inc..

What drugs are being tested in NCT06038838?

Interventions in NCT06038838: Tioga TMVR System.

What condition does NCT06038838 study?

NCT06038838 studies Mitral Regurgitation.

Is NCT06038838 still recruiting?

NCT06038838 is currently recruiting now. Last updated 12 November 2025.

Last reviewed 2025-11-12 · How we verify

NCT06038838

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility Study of the Tioga TMVR System

Recruiting now NA Last updated 12 November 2025

What this trial tests

NA trial testing Tioga TMVR System in Mitral Regurgitation in 30 participants. Currently enrolling.

Timeline

1 April 2024

Primary endpoint
1 July 2026

1 July 2028

Quick facts

Lead sponsor	Tioga Cardiovascular, Inc.
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 April 2024
Primary completion	1 July 2026
Estimated completion	1 July 2028
Sites	5 locations across Georgia, Lithuania, Paraguay, Brazil

Drugs / interventions tested

Tioga TMVR System

Conditions studied

Mitral Regurgitation — all drugs for Mitral Regurgitation →

Sponsor

Tioga Cardiovascular, Inc.

Who can join

18 and older, any sex, with Mitral Regurgitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is aimed to assess the safety and feasibility of the Tioga TMVR System in treating patients with symptomatic MR (MR\>=3+)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mitral Regurgitation

Currently open trials in the same condition.

NCT07450911 — A Clinical Study Evaluating the Replacement of the Native Mitral Valve Using the ReValve System · Phase 1 · recruiting
NCT07366723 — The Role of cardIac magNeTic rEsonance in surGical Decision Making in Patients With Severe pRimAry miTral rEgurgitation · NA · active not recruiting
NCT07007143 — STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication fo · Phase 4 · recruiting
NCT07108907 — Outcome Registry and Assessment of New Edge-to-Edge Repair · recruiting
NCT06901466 — STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for O · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06038838 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tioga Cardiovascular, Inc.
Last refreshed: 12 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06038838.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing